OMG Akki
im just putting it out there
Someone else who is more learned than self is saying what I’m saying..
FDA should never of agreed to the last review swayed by the patent
sympathetic plea.
FDA was correct : they knew it was not going to show any benefit (efficacy)
Does not compete with Atl1102 @$3 mill Usd
Sarepta is not making a profit with the other drugs
Imo : Sarepta will have to get into negotiations with PER
We are all waiting for the Tox results.. For Per to get into the USA .
FDA review re Sarepta 21/6/24 expanded gene therapy, page-3
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
